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Abstract 
Background: 
Diabetes Mellitus is a chronic disease associated with significant morbidity and healthcare 
costs. Although diabetes disease management programs have been shown to improve 
intermediate outcomes such as glycemic control, it is unclear whether these programs improve 
healthcare utilization outcomes. 
 
Objective: 
To conduct a systematic review and meta-analysis of randomized control trials (RCTs) to 
assess the effectiveness of disease management programs for reducing hospitalizations and 
emergency department (ED) visits in a population of adults with type II diabetes mellitus. 
  
Methods: 
I searched MEDLINE®, Embase, and Cumulative Index to Nursing and Allied Health Literature 
(CINAHL)® to find RCTs (published before January 1st, 2014) of disease management 
programs for adults with type II diabetes. Included trials had to measure either hospitalizations 
or ED visits. I extracted relevant data from each trial and graded the risk of bias of each 
included trial. I then performed a meta-analysis of those programs that reported similar 
measures of utilization rates.  
 
Results: 
Six RCTs met inclusion criteria.  Four studies were conducted in the United States, one in 
Brazil, and one in South Korea.  Educational and coaching components were the most common 
intervention components; care coordination and independent treatment adjustment by the case 
manager were less common.  All six trials reported on ED utilization.  Of these, three were able 
to be included in the meta-analysis to determine changes in ED utilization.  Four studies 
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reported on hospitalizations; two of these were able to be included in the meta-analysis to 
determine changes in hospital utilization.  A single study by Wu et al., showed borderline 
significance in its ability to reduce ED utilization with a risk ratio of 0.45 (95% confidence interval 
0.21-0.98).  However this statistically significant outcome was only present with an intention-to-
treat analysis and was not present in the authors own as-treated analysis.  No other study, or 
pooled meta-analysis found a significant difference between disease management programs 
and usual care for reducing health care utilization. 
 
Conclusion: 
Disease management programs show no benefit over usual care for reducing ED visits or 
hospitalizations.  Overall, I found few studies that met inclusion criteria. Future trials may help 
determine whether diabetes disease management programs affect healthcare utilization rates.  
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Introduction 
Background of Diabetes Mellitus 
Diabetes Mellitus is a chronic disease associated with significant morbidity and healthcare 
costs.  As of 2014, the Center for Disease Control and Prevention (CDC) estimated that nearly 
29.1 million people in the United States (U.S.) suffer from diabetes. Furthermore, the prevalence 
of diabetes among adults in the U.S. was 9.3% in 2014, up from about 3.5% in 1980 (1–3). The 
CDC estimates that the prevalence of diabetes could increase up to 1 in 3 adults by 2050(4).  
The majority of this growth has been in patients with type II (or non-insulin dependent) diabetes.  
This is supported by an increasing and correlated prevalence of pre-diabetes, a partially insulin 
resistant condition, which is a known precursor to type II diabetes(2,3).  The CDC estimates that 
90%-95% of diabetes in the U.S. is type II diabetes.  Increasing levels of obesity in the U.S. 
population is thought to contribute to the increased prevalence of type II diabetes; both obesity 
and type II diabetes are caused (in part) by low levels of physical activity and poor diet(1,2). 
   
Diabetes mellitus, hereafter referred to simply as diabetes, is associated with several adverse 
health outcomes, such as chronic kidney disease (CKD), microvascular complications, (e.g., 
diabetic retinopathy) macrovascular complications (e.g., cardiovascular disease [CVD]), and 
others.  Microvascular complications are known to result as a direct consequence of chronic 
hyperglycemia(5,6).  Macrovascular complications have so far been shown to be non-causally 
associated with chronic hyperglycemia(7).  A clear epidemiological association is present 
between worsening chronic hyperglycemia and increased  risk of CVD endpoints, such as 
myocardial infarction (MI).  This evidence is a result of several well-powered, non-randomized 
prospective cohort studies(8–10).  Randomized trials have suggested trends towards reduction 
in CVD endpoints, such as MI, as a result of direct improvement in hyperglycemia.  However, 
the results have been non-statistically significant(5,6).   
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Diabetes incurs significant financial strain to both the healthcare system, and to patients.  The 
CDC estimates that as of 2014, the costs related to diabetes care in the U.S. reached $176 
billion in direct medical costs and $69 billion in indirect medical costs(2).  This is up from 2007 
where direct and indirect medical costs for diabetes costs were estimated to account for $153 
billion and $65 billion, respectively(11).  Direct medical costs account for money directly 
attributable to medical care, such as provider, hospital, and medication costs.  Indirect costs 
include such aspects as lost productivity.  As of 2014, the CDC estimates that a person with 
diabetes uses 2.3 times more medical services, than a person without diabetes(2). 
 
Following the evidence that improvement in blood glucose levels reduces diabetic complication 
rates, pharmacologic management of hyperglycemia has become a mainstay of diabetes care.  
Foundational studies in this area have been the Diabetes Complications and Control Trial, the 
United Kingdom (UK) Prospective Diabetes Study, and a study by Ohkubo et al. on intensive 
insulin regimens for prevention of microvascular complications(5,6,12). The Diabetes 
Complications and Control Trial demonstrated that in the treatment of type I (or, insulin 
dependent) diabetes, intensive therapies that maintained blood glucose near normal physiologic 
levels reduced diabetic complications, such as kidney disease, retinopathy, and neuropathy(5).  
Yasuo Ohkubo and colleagues applied this same principle to individuals with type II diabetes by 
demonstrating a reduction in microvascular complications as a consequence of intensive insulin 
regimens in this population(12).  Finally, the UK Prospective Diabetes Study showed that in 
individuals newly diagnosed with type II diabetes, a similar improvement in blood glucose levels 
precipitated a similar decrease in diabetic complications, regardless of whether an insulin or an 
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History of Disease Management Programs 
Despite the wealth of evidence related to best practice in clinical diabetes care, the prevalence 
of diabetes continues to increase, as to associated costs of medical treatments, both in the U.S. 
and abroad(1,13,14).  Many feel that traditional clinical interventions that often focus on 
pharmacologic therapy alone have been insufficient in addressing diabetes(15).  Diabetes is a 
chronic condition that requires regular self-care with frequent blood glucose monitoring, and 
often frequent clinical monitoring and adjustment of chronic pharmacological therapy.  In 
addition, multifactorial interventions to improve patient adherence are essential for prevention of 
diabetes related complications.  For example, interventions that focus on maintaining a healthy 
body mass index, receiving regular disease specific screenings, and maintaining a healthful diet 
are felt to be important in the overall care of patients with diabetes (16).  In response to this 
complex set of recommendations, the Community Preventative Service Task Force (Task 
Force), in 2002, recommended the use of disease management and case management 
services in order to improve outcomes related to diabetes care(15).  The Task Force defined 
disease management as an “Organized, proactive, population-based, and integrated” set of 
interventions that focused on the following: 1) the structure, processes, and resources of a 
health care delivery system; 2) provider knowledge, attitudes and behavior towards screening 
and treatment; and 3) patient knowledge, self care behaviors, and psychological mediators(15). 
   
The Disease Management Association of America (DMAA) has offered an alternative definition 
of disease management.  They state that a disease management program “supports the 
physician or practitioner/patient relationship and plan of care; emphasizes prevention of 
exacerbations and complications utilizing evidence-based practice guidelines and patient 
empowerment strategies; and evaluates clinical, humanistic, and economic outcomes on an on-
going basis with the goal of improving overall health (pg. 116)”(17).   
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In both cases, these definitions share a focus on population-health, an emphasis on evidence-
based interventions, and a purpose to complement, rather than supplement, the traditional 
provider/patient interaction. 
 
Efficacy of Diabetes Disease Management Programs for Glycemic Control 
Following recommendations of the Task Force, a number of randomized control trials (RCTs) 
have provided evidence as to the efficacy of disease management programs for lowering 
hemoglobin A1c (HbA1c) in diabetic populations.  Compared to usual care, they have led to 
better glycemic control for patients with diabetes.  However, the absolute effects on HbA1cs 
have been modest.  A meta-analysis including 41 of these studies that compared disease 
management programs with standard care found an average decrease in HbA1c of 0.38% (95% 
CI 0.29% to 0.47%), favoring the disease management interventions (17).  This review, along 
with another systematic review, found that disease management programs showed greater 
effectiveness if they included the following:  1) community educators 2) expanded scope care 
providers, such as pharmacists and nurses that could independently adjust treatments 3) 
incorporated treatment algorithms, and 4) provided more frequent contact with patients(17,18).  
In particular, the systematic review by Pimogouguet et al. showed that using expanded scope 
care providers in a disease management program led to an absolute HbA1c decrease in 0.6% 
versus a decrease of 0.28% in those programs that did not use expanded scope care providers 
(p<0.001)(17).  Likewise this review also found that programs which contacted patients several 
times per month had greater efficacy than programs which contacted patients less than one 
time per month; an absolute decrease in HbA1c of 0.56% versus 0.3%, respectively (p=0.033). 
 
Efficacy of Diabetes Disease Management Programs on Healthcare Utilization  
While the effect of diabetes disease management programs on intermediate and clinical 
outcomes is well characterized, it is unclear whether diabetes disease management programs 
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improve healthcare utilization outcomes such as rates of hospitalization and emergency 
department (ED) visits.  The question of reduced utilization, specifically, has become even more 
relevant as the Patient Protection and Affordable Care Act (ACA) has generated renewed 
interest in managed care.  New provisions in the ACA allow for the creation of Accountable Care 
Organizations (ACOs).  These new care structures will allow health systems to share in cost-
savings generated by better provision of care, but conversely will require them to begin 
accepting some of the financial risk of the populations they care for(19,20).  This financial 
impetus will likely spur health systems to further explore and invest in novel care structures, 
such as disease management programs, in the hopes of generating cost saving interventions 
for complex patients.  One potential mechanism of cost-savings comes from the shifting of costs 
from expensive inpatient services, to less expensive outpatient services.   
 
The literature regarding the ability of diabetes disease management programs to reduce 
hospitalizations and ED visits is limited.   Several non-randomized prospective trials and 
retrospective studies have examined this topic(21–26).  All of the prospective studies were able 
to observe a reduction in hospitalization or ED visits for patients enrolled in diabetes disease 
management programs.  These results ranged from relative reductions of 18% to 
51%(23,25,26).  However, the prospective studies were all based on a pre-intervention, post-
intervention study design, with no control group. Even when performed well, pre-post 
intervention study designs are influenced by the Hawthorne effect and regression towards the 
mean, which confound the true results of the study.  Regression towards the mean, in particular, 
is thought to play a significant role in influencing disease management studies(27,28).  This is 
due to the fact that disease management programs are often targeted towards the sickest 
patients with the highest levels of health care utilization.  Because disease management 
programs target these outliers, some portion of the patients they treat will likely get better on 
their own, regardless of what intervention they receive(27).   
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In the case of the studies that used a retrospective cohort design, several used propensity score 
matching techniques in order to select a relevant control population.  The effect size from these 
studies was more limited and ranged from no difference to a reduction in hospitalizations of 
17.5%(21,22,24).  The propensity score matching technique is one way that has been 
advocated for retrospective studies to select a relevant control population with similar 
characteristics and thus compensate for selection bias and natural regression towards the 
mean(27). 
 
Finally, not all of the evidence regarding disease management programs has been favorable.  A 
recent study by McCall and Cromwell likely represents the largest randomized control trial of 
disease management programs to date(28).   This study reported on the Centers for Medicare 
and Medicaid Services (CMS), Medicare Health Support Pilot Program.  This pilot program was 
a 36-month long, randomized trial involving 15 commercial disease management programs and 
measured their ability to improve process measures, reduce health care utilization, while 
maintaining cost neutrality.  The programs targeted a total of 242,417 Medicare patients who 
had either diabetes mellitus or heart failure and who had medical costs 35% above average.  
About half of the participants had diabetes, while the other half had either heart failure alone or 
heart failure and diabetes concurrently.  In aggregate, the trial reported no difference in hospital 
admissions or ED utilization between the disease management group and usual care.  In 
addition, only 14 of the 40 process measures showed consistent and statistically meaningful 
improvement in favor of disease management.  Finally, none of the disease management 
programs studied were able to maintain cost neutrality; the disease management intervention as 
a whole was significantly more expensive than usual care(28). 
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It should be noted that all of these programs were commercial programs that were poorly 
integrated with the patients’ care teams.  Likewise, this trial targeted both patients with diabetes 
and patients with heart failure, rather than patients with only diabetes. There may be important 
differences in costs and frequency of utilization among these patients.  Finally, the study noted 
that all the disease management programs struggled to recruit “ideal patients”.  Their 
interpretation of this difficulty was that the patients who were randomized were, in general, 
healthier than what might be considered “ideal” for a disease management intervention. The 
authors suggest that this healthier population may not have benefited as much from the 
intervention than would a population with greater disease severity, thus potentially reducing the 
effect size(28,29).  All of these issues limit the applicability of this study’s results. However, this 
study does challenge the assumption that disease management programs lead to reductions in 
healthcare utilization and cost, and suggests that a closer and more critical look at the literature 
surrounding diabetes disease management programs is needed. 
 
To address this issue, I conducted a systematic review and meta-analysis on the effect of 
disease management programs in reducing hospitalizations and ED visits. To my knowledge, no 
prior study has synthesized this evidence. 
 
Methods 
Defining Disease Management 
So far there has been no clear consensus on what constitutes a disease management program.  
This is likely due to the different possible intervention components that can characterize disease 
management programs.  Additionally, disease management programs may overlap with other 
non-disease management interventions that aim to improve healthcare delivery.  Therefore, in 
order to develop my inclusion and exclusion criteria, I considered several definitions or 
conceptualizations of “disease management”.  I was motivated by a need to determine a 
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definition of disease management that would both be broad enough to allow for differences 
between programs, but also a definition that was concrete enough to discern between disease 
management programs and other changes to health care delivery. 
 
The definitions previously offered by the DMAA and Task Force both allow for differences in 
interventions between disease management programs, but also emphasize a set of core 
principles of all disease management programs.  Specifically, that they are evidence based, 
population health focused, and complementary to clinical care.  However, although they useful 
in identifying possible disease management programs, I felt that neither definition was 
discriminatory enough to discern between disease management programs and other health 
services interventions for the purpose of this literature review.   
 
As part of their systematic review of disease management programs to improve blood glucose 
control, Pimouguet et al. (2011) created a more specific working definition of disease 
management programs with the goal of identifying specific components that could make up 
such a program. The authors defined disease management as an “ongoing and proactive 
follow-up of patients that includes at least two of the following five components: patient 
education (dietary and exercise counseling, self-monitoring, and knowledge of disease and 
medication); coaching (the disease manager encourages the patient to overcome psychological 
or social barriers that impede autonomy or improvement in medication compliance); treatment 
adjustment (the disease manager is able to start or modify treatment with or without prior 
approval from the primary care physician); monitoring (the disease manager gets medical data 
from the patient); and care coordination (the disease manager reminds the patient about 
upcoming appointments or important aspects of self-care and informs the primary care 
physician about complications, treatment adjustment or therapeutic recommendations).”(17).   
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I chose this definition to inform my inclusion and exclusion of trials as it relies on a combination 
of factors when defining a program and appeared to be a good fit for the diabetes care 
management literature.   It allows for flexibility of intervention components within a single 
program.  And, although the definition allows for flexibility, it is also built upon a relatively 
discrete and well-characterized set of components allowing for the inclusion of similar 
interventions during abstract and full-text review. 
 
Search Criteria 
With the help of a health-sciences librarian, I conducted a literature search using MEDLINE®, 
Embase, and Cumulative Index to Nursing and Allied Health Literature (CINAHL)® for relevant 
English-language studies published prior to Jan 1st 2014.  My search terms included: “Diabetes 
Mellitus, Type 2”, “Preventive Health Services”, “Patient Care Management”, “Case 
management” “Health Education”, “Counseling”, “Emergency Department”, “Emergency health 
service”, “Emergency ward”, “Emergency Room”, “Hospitalization”, and “Hospitals/Utilization 
(MeSH term)”.  The full search criteria are presented in Appendix 1. 
 
Study Selection and Inclusion and Exclusion Criteria 
 Table 1 outlines inclusion and exclusion criteria.  Briefly, I included RCTs of 
interventions that fit the definition of disease management described by Pimouguet et al.(17).  I 
specifically excluded transitional care interventions given that the scope and goals of these 
programs are often different from longitudinal outpatient disease management programs.  I 
defined transitional care programs to be time-limited interventions specifically aimed at 
increasing coordination of care for patients newly discharged from the hospital , avoidance of 
readmission, or both.  Of note, I specifically did not exclude trials from other countries, as I felt 
that major principles regarding coordination of care for individuals with chronic diseases would 
be broadly applicable, regardless of country of origin.  I also chose to focus on type II diabetes 
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as it accounts for a large proportion of the global diabetes burden, especially in the elderly, 
comorbid population that is likely to receive disease management services. 
 
Study titles and abstracts were reviewed for relevance against the inclusion/ exclusion criteria. I 
then reviewed the full text of those articles that either fit inclusion criteria based on the abstract 
or if it was unclear whether the study should be included or excluded from the analysis.  
 
Data Abstraction and Quality Assessment 
Studies that met inclusion criteria at full text review were included in data abstraction.  For each 
study, I recorded in an outcomes table the following information: study identifiers, study design 
features, population characteristics, description of the intervention and comparator, baseline 
population health care utilization, and health utilization outcomes.  If studies reported on multiple 
time points for health care utilization, only the cumulative outcome for the entire study period 
was abstracted. 
 
I assessed the internal validity (or quality) of each included trial using a predefined set of criteria 
that assessed the following: selection bias, performance bias, detection bias, attrition bias, 
reporting bias, and possible confounding.  These criteria were based on the process of the U.S. 
Preventive Services Task Force and the National Health Service Centre for Reviews and 
Dissemination (United Kingdom)(30,31).  From these criteria, I then rated each study in terms of 
overall risk of bias: low, medium, and high.  All studies, regardless of risk of bias were included 
in the review.   
 
Meta-Analysis of Utilization Outcomes 
In order to increase comparability of outcome measures, I used information provided by the 
studies to calculate relevant measures of association. For example, when possible and where 
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count data for health care utilization (i.e., number of hospitalizations and ED visits) as well total 
person-time was given or could be estimated, I calculated incidence rate ratios (IRR).  Where 
the proportion of individuals admitted was given, I attempted to calculate risk ratios (RR), and if 
this was not possible I estimated an odds ratio (EOR). In all cases I calculated utilization 
measures using an intention to treat framework.  This meant that outcome measures, and 
subsequent measures of association were calculated using the reported group sizes 
immediately after randomization, rather than on an as-treated basis.  In all cases an association 
measure less than 1 favors disease management for reducing health care utilization and an 
association measure greater than 1 favors usual care for reducing health care utilization. 
 
Because disease management programs are heterogeneous by nature of the multiple 
interventions they can include, I used a random effects model when I calculated a pooled effect 
size.  I included in the same model, studies that had similar reported, or calculated measures of 
association.  In all cases, a p value of 0.05 or less was considered to be statistically significant, 
with 95% confidence intervals (CI) given for association measures.  I used both a chi-squared 
statistic and an I2 statistic to assess for differences in the studies that resulted from statistical 
heterogeneity(32).  All analyses were conducted using the “metafor” package for R 3.0.2(33,34). 
 
Results 
Literature search and screening 
512 original articles were identified from all database searches.  Of these, 6 articles met the 
inclusion criteria for this review.  The process of study selection is summarized in Figure 1.   
 
Characteristics of Study Populations 
All six included RCTs evaluated a disease management program compared to usual care.  The 
mean age for the study populations was 60 years old with a range of 51 to 69 years.  The racial/ 
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ethnic distribution of subjects within each study was relatively homogeneous, but the racial/ 
ethnic distribution of subjects between studies was remarkably heterogeneous.  Two studies, 
Wu et al. conducted in Taiwan(35) and Borges et al. conducted in Brazil(36), did not report 
racial/ ethnic distribution.  Two other studies from the U.S., Gary et al. and Babamoto et al. 
included only African Americans and Hispanics, respectively(37,38).  The other two studies 
conducted in the U.S., from Aubert et al. and Taveira et al. had no racial/ ethnic inclusion criteria 
and enrolled mainly Caucasians, 73% and 99%, respectively(39,40).  With one exception, the 
studies recruited a majority of women.  The exception, a trial by Taveira et al., was conducted 
through the Veterans Administration and recruited only 2% women.  The remaining five studies 
had an average demographic composition of women of 66% with a range of 60% to 
73.5%(35,36,38–40).   
 
Five of the six studies included only people with type II diabetics.  The study by Aubert et al. 
included primarily type II diabetics, but type I diabetics accounted for 17% and 8% of the 
intervention and control cohorts, respectively(39). Five of the six studies reported the average 
glycemic control of their population at enrollment, measured via HbA1c; the average HbA1c was 
8.5% with a range of 7.7% to 9.5%.  In all cases, HbA1c was similar between intervention and 
control groups.  Duration of diabetes diagnosis also varied within and between studies.  
Babamoto et al. specifically included only patients diagnosed with diabetes in the last six 
months(38).  Three of the remaining five studies included information regarding duration of 
diabetes diagnosis for their cohorts. The average duration of diabetes was 8.8 years.  In all 
three cases, this duration was similar between intervention and control cohorts. 
 
Studies varied in other inclusion and exclusion criteria as well.  Most of the trials had an 
inclusion age of 18 years old.  Two of the studies required participants to be 30 years or older or 
25 years or older(35,37).  Five of the studies excluded participants for additional reasons: 1) 
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pregnancy or gestational diabetes(38–40), 2) medical or psychiatric conditions that would 
interfere with self care(35,39,40), 3) other complications (hepatocellular carcinoma, infected with 
human immunodeficiency virus [HIV])(36), 4) Blood glucose control (exclusion of HbA1c under 
7%, or inclusion only if over 6.5%)(39,40). 
 
Intervention Description 
All of the included trials used either a pharmacist or a nurse case manager to deliver the 
intervention.  Two of the six studies also had an intervention with a trained layperson that 
worked as a community health worker.  Gary et al. provided the community health worker 
intervention concurrently with case manager services(37).  Babamoto et al. provided the 
community health worker as an alternate treatment arm and was unique in having three study 
arms, one arm that received only the community health worker intervention, one arm that 
received only a case manager, and a usual care arm(38).  Four of the six interventions enabled 
the case manager to independently adjust pharmacologic treatment, based on a pre-determined 
treatment algorithm(36,39,40).  
 
Three of the six studies used an initial in-person interaction along with follow-up either via 
telephone or a mix of telephone or in-person follow-up(35,37–39).  Two of the six studies used 
only in-person interactions between the disease manager and patient(36,40).  Five of the six 
studies had interactions between the disease management program and the patient at least 
once a month.  Gary et al. reported the least frequent interactions, with interactions at least 
three times per year for the community health worker and at least once per year for the nurse 
case manager.  This led to a minimum of four patient interactions per year, with more frequent 
interactions if necessary(37).  All the studies varied significantly as to which of the five aspects 
of a disease management program, (outlined in the methods section above), were included in 
the intervention.  All six studies included an educational component to their programs, four 
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included coaching components and another four included active monitoring of their participants.  
The least likely components to be used in the disease management programs were care 
coordination and treatment adjustment, with only two and three studies reporting use of these 
components, respectively. 
 
In all six of the studies, the comparison group was described as receiving, “usual”, or “standard 
care”, with a physician provider.  Three studies specifically described interventions (in addition 
to provider visits) that were part of standard care.  In the study by Wu et al., patients who were 
newly diagnosed with diabetes received 15 minutes with a nurse educator and a nutritionist(35).  
In the study by Taveira et al. all patients with diabetes received two hours of diabetes education 
every week, for four weeks, followed by monthly education sessions(40).  Patients receiving 
standard care in the study by Gary et al. received automated screening reminders every six 
months(37). 
 
Description of Reported Outcomes 
Four studies measured health care utilization as a primary or secondary outcome.  The other 
two studies measured utilization as a “harm”; neither of these studies described how utilization 
outcomes were collected(39,40).  All six of the studies measured and reported on frequency ED 
visits.  Only four out of six studies also reported on rates of hospitalizations.  In the majority of 
the cases, five out of six studies, all cause hospitalization and ED usage was measured.  The 
study by Wu et al. chose to measure ED visits and hospitalizations that were related to diabetes 
only, and did not provide a measure of “all-cause” utilization (35).  Five of the six studies 
reported on the proportion of participants who were hospitalized or visited the ED.  The only 
exception was the trial conducted by Gary et al., which reported the total number of visits to the 
ED, and total number of hospitalizations.   
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Studies varied in how utilization rates were ascertained.  In two studies it was unclear how 
utilization rates were measured(39,40),  two studies used self report(35,38), Borges and 
colleagues expressly used claims data(36).  And Gary et al. used a combination of patient 
medical records and inquires into local hospitals in order to determine utilization rates(37). 
 
Studies varied in the length of outcomes that were collected.  Three studies had follow-up times 
of six months(35,38,40).  Two studies had follow-up times of one year(36,39).  Tiffany Gary and 
colleagues followed subjects out to 36 months(37).  
 
Description of Setting: 
As stated above, four of the six studies were conducted in the U.S.  The study conducted by Wu 
et al. took place in Taiwan and the study by Borges et al. took place in Brazil.  In all cases the 
interventions were conducted in an outpatient setting.  Borges et al. recruited subjects who were 
patients of an endocrinology clinic(36).  The remaining studies recruited subjects from the 
surrounding area or subjects who were patients of the health system affiliated with the study.  A 
table summarizing these interventions is given in Table 2 and a more complete summary of 
disease management criteria that were fulfilled by each intervention is given in Appendix 2. 
 
Description of Quality 
I rated one trial as having low risk of bias(37).  Four were rated as medium risk of 
bias(35,36,39,40).  The Babamoto et al. trial was rated high risk for bias both due to high 
attrition as well as high risk of measurement bias.  The authors relied on self-report data alone 
to determine utilization rates.  The most common methodological problem encountered was 
high rates of attrition.  Another common methodological problem was measurement bias (e.g., 
one method, such as self-report only to determine utilization outcomes). A more complete 
description of quality determination is given in Appendix 3. 
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Emergency Department Utilization 
Three studies reported outcomes related to ED visits in a way that allowed pooling of data in a 
meta-analysis to determine a pooled risk ratio (Figure 2).  Because the Babamoto et al. study 
included two study arms, each arm was treated as a separate data point in the meta-analysis.  
Although the pooled estimate favored disease management programs versus standard care in 
the reduction of ED visits, this result was not statistically significant, (RR 0.78; 95% C.I. 0.53-
1.15), the  statistical heterogeneity of these studies in the random effects model was low, I2 = 
3.6%(38–40). 
 
The remaining three studies allowed for the calculation of three different association measures.  
Wu et al. reported only diabetes related ED visits and found no difference between the two 
groups, (RR 0.63; 95% CI 0.35 – 1.15)(35). Using the information provided by Borges et al. I 
was able to calculate an estimated association measure, (EOR 0.70; 95% CI 0.30 – 1.64)(36).  
Finally, Gary et al. also reported a non-significant decrease in the number of ED visits, (IRR 
0.84; 95% CI 0.61 – 1.15)(37).  In five of the six trials, the measure of association showed a 
trend towards reduced ED visits in favor of the disease management intervention, but none of 
these differences were statistically significant.  A summary of reported ED visits and their 
related association measures are given in Table 3.   
 
Hospital Utilization 
I included the last two studies, from Aubert et al. and Taveira et al., in a meta-analysis of the 
effect of disease management programs for the reduction of all-cause hospitalization(39,40).  
This meta-analysis is given in Figure 3.  The pooled estimate slightly favored disease 
management programs for reducing hospitalizations for patients with diabetes, when compared 
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to standard care.  However, the pooled result was not statistically significant (RR 0.91; 95% CI 
0.39 to 2.13).  Again the heterogeneity measure between these two studies was low, I2 = 0. 
 
Four studies reported on hospital utilization rate.  Again, Wu et al. reported on only diabetes 
related hospitalizations.  Of note, this group reported no significant difference in hospitalizations.  
However, in my intention-to-treat analysis, the reduction in hospitalizations favoring disease 
management obtained statistical significance, (RR 0.45; 95% CI 0.21-0.98).  Wu et al. 
performed their analysis on individuals who completed the program with no mention of how 
missing data was handled.  Gary et al. again reported a non-significant decrease in the number 
of hospitalizations, (IRR 0.83; 95% CI 0.64-1.07).  A summary of reported hospitalization rates 
and their related association measures are given in Table 4.  
 
Discussion: 
Across the six included trials in this review, diabetes management programs appear to offer no 
additional benefit above usual care in reducing health care utilization rates.  No single study or 
meta-analyses of the included trials found a statistically significant reduction in health care 
utilization.  The significant heterogeneity in terms of how outcomes were reported limited my 
ability to pool results.  Effect sizes for reductions in ED usage varied considerably from a 
relative risk reduction of 76%, to a level of equal efficacy, when compared to standard care.  
The variability in effect size regarding reduction of hospitalizations was less, but still 
considerable, from a 55% to a level of equal efficacy.  Taken in aggregate, these results 
suggest that disease management programs for diabetic patients perform no better than usual 
care in their ability to prevent ED visits and hospitalizations.  
 
These results are consistent with other studies and reviews of disease management programs 
that have found lackluster results in regards to the efficacy of disease management programs.  
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Most notably, the results of this review are in accordance the Task Force’s findings(15).  In the 
review conducted by the Task Force, their results were suggestive of a reduction in health 
utilization, but in the end they were unable to show a statistical difference between disease 
management and usual care for any of the identified studies. The pooled meta-analysis of 
disease management studies, presented here, suggests a trend towards decreased utilization; 
33% for ED visits, and 9% for hospitalizations that was not statistically significant (37,38,40).   
 
Since few trials met inclusion criteria, we were not able to assess whether these programs are 
more or less efficacious for certain subgroups of patients. Likewise, the limited number of 
studies and the variability in their incorporation of the five components of disease management 
programs laid out by Pimouguet et al., meant that I was not able to assess whether the different 
possible components of disease management programs were more or less effective than one 
another.  My review did show, however, that educational components were the most common 
intervention incorporated, with all six studies incorporating some educational aspect to their 
program.  Conversely, care coordination and treatment adjustment components were the least 
common interventions used (Appendix 2).  This may reflect an easier ability to implement 
educational components to a program, or may alternatively reflect a perception that patient self-
care education is an important aspect of all diabetes care(16). 
 
Limitations of this Systematic Review and Meta-Analysis 
Due to limitations in time and resources, I was not able to perform a hand search of the citation 
lists provided in other studies or hand search systematic reviews on the topic of disease 
management for diabetes.  A manual search of relevant disease management studies may have 
allowed me to identify additional disease management trials that reported on health care 
utilization. Similarly, a search of grey literature was not performed. This may have identified 
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unpublished studies or unpublished utilization outcomes from other trials that could provide an 
assessment of publication bias in this literature base. 
 
Additionally, this study was limited to RCTs.  Non-randomized trials have been advocated as 
one way to expand the body of knowledge regarding health services research(27,29). 
Therefore, the body of evidence regarding disease management programs would have been 
larger had non-randomized prospective studies and retrospective studies been included. 
However, because of the significant heterogeneity that already exists amongst types of disease 
management programs, I attempted to limit other aspects of the review in order to promote 
comparability.  Future reviews may be able to successfully incorporate these other study 
designs as a way of broadening the knowledge base. 
 
Limitations in the Literature 
A major limitation of this literature was the small number of studies identified related to this 
topic.  As discussed above, there may be a potential for publication bias or outcome reporting 
bias related to this literature and this could be assessed in future work. For the trials that were 
identified, there was significant heterogeneity in how authors measured and reported health 
care utilization outcomes.  This greatly limited my ability to meaningfully pool the outcomes in 
order to create an aggregate estimate of effect size.  As noted above, many of the studies did 
not have a primary goal of measuring health care utilization.  In those studies, therefore, the 
reliability of the measures may be in question and this therefore limits the conclusions that can 
be drawn.  Finally, many of the studies reviewed contained less than 100 subjects in each arm 
and measured only a handful of healthcare utilization events.  These small numbers of 
utilization events limits the ability to draw statistically meaningful conclusions from the studies.  
 
Future Directions For Research 
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This review may add the most towards recognition of the scarcity of evidence that still exists 
regarding the ability of diabetes disease management programs to improve health care 
utilization outcomes.  As part of addressing this issue, future studies will need to focus on two 
aspects of study design: increased statistical power (e.g., larger sample sizes), and 
determination of utilization outcomes through multiple, valid measures.   
 
Additional well-designed studies will allow two important questions to be addressed.  This first is 
whether diabetes disease management programs are effective for reducing health care 
utilization in certain sub-groups of diabetic patients.  Theoretically, patients who are sicker will 
stand to benefit more from the services offered by disease management programs.  The 
systematic and improper selection of patients who are “too healthy”, has been one justification 
for the poor performance of past disease management programs(28,29).  Future studies may 
show whether the selection of a source population that has poorer health metrics improves the 
effectiveness of disease management programs.  Additionally, the majority of the trials included 
here lasted less than one year, this is significantly shorter than the time it takes for most diabetic 
complications to develop.  Future studies should also therefore consider lengthening the study 
period to help assess effectiveness of disease management programs.  The second question is 
whether certain components of disease management programs prove to be effective at reducing 
health utilization.  In this regard, investigators may do well to replicate the components of 
diabetes disease management programs that have been most effective for improving 
intermediate outcomes (e.g. HbA1c).  Future studies should therefore seek to provide patients 
with frequent contact with case managers that are able to independently adjust patient 
treatment regimens.  Likewise they should rely less heavily on patient education 
components(17,18), which perhaps are easier to implement, but have shown little efficacy in 
improving intermediate outcomes. 
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It is likely that in response to increasing costs related to the treatment and morbidity of diabetes, 
health systems will continue to restructure their diabetes care by incorporating interventions 
such as disease management programs.  A better understanding of how these programs affect 
health care utilization is needed in order to ensure the resources are allocated in a way that 
benefits the patient.  In summary, while this review has shown no difference in the ability of 
diabetes disease management programs to reduce health care utilization when compared to 
usual diabetes care, it has highlighted the significant gaps in knowledge that still exist in regards 
to these programs and offers possible solutions for rectifying those gaps.   
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Table 1 - Inclusion and Exclusion Criteria 
Study 
Aspect 
Inclusion Criteria Exclusion criteria 
Language Full text is in English Full text is in another language 
Population Adults with type II diabetes (Included 
if the majority of subjects had type II 
diabetes) 
Majority of subjects had type I 
diabetes. 
Intervention Designated disease manager who 
has longitudinal relationship with 
patient and provides 2 of the 
following: patient education, 
coaching, treatment adjustment, 
monitoring, or care coordination.  
Disease manager can be an allied 
health professional (e.g. pharmacist, 
nurse, etc.) or trained layperson. 
 
Intervention is targeted towards 
diabetes care. 
Intervention addresses only 
one or none of these 
components (e.g., education 
only interventions).  
Transitional care programs 
(e.g., time limited and focused 
on populations transitioning 
from hospital to home).  
 
 
Intervention is primarily 
targeted towards another 
chronic disease (e.g., heart 
failure). 
Comparison Standard care for diabetic patients Comparative effectiveness 
trials (e.g., studies comparing 
one type of intervention with 
another). 
Outcome Emergency department (ED) visits 
or hospitalizations. 
Healthcare costs, risk 
prediction tools, intermediate 






All other study designs (e.g., 
non-randomized trials, cohort 
studies, case-control studies, 
epidemiological studies) 
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Figure 1 – Disposition of Articles 
PubMed: 274 articles	  
CINAHL: 72 articles	  
Embase: 218 articles	  
Total: 564	  
512 Original Articles	  
114 Abstracts	  
36 Full Text	  
6 Included	  
52 Duplicates	  
Not English: 1	  
Wrong population: 73	  
Wrong intervention: 189	  
Wrong comparator: 3	  
Wrong outcome: 31	  
Wrong study design: 101	  
Wrong population: 4	  
Wrong study design: 42	  
Wrong intervention: 25	  
Wrong outcome: 7	  
Wrong intervention: 5	  
Wrong comparator: 1	  
Wrong outcome: 2	  
Wrong study design: 22	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Control   
(77) 
Standard care plus 10-15 minutes of education by nurse educators 
and 10-15 minutes by a nutritionist.  
Intervention 
(81) 
Standard care plus - 4 weekly group education sessions led by a 
nurse case manager.  Follow-up call by nurse 8-16 weeks after 
initiation of program. 
Aubert, 
1998 (12) 
Rate of all 
cause 
hospitalizations 
and ED visits 
Control  
(67) Standard care 
Intervention 
(71) 
Standard care plus – Initial visit with the nurse case manager with 
follow-up 2 weeks later.  Case manager could independently alter 
the treatment algorithm.  Also provided guidance for meal planning 
and exercise.   The nurse care manager had weekly follow up calls 
if the patient used insulin.  The nurse care manager called every 
other week if they were using an oral hypoglycemic.  Patients also 
received a 5 week educational program with quarterly follow-up. 
Gary, 
2009 (36) 
Rate all cause 
hospitalizations 
and ED visits 
Control  
(273) 




Standard care plus - Community health workers focused on 
nutrition, physical activity, medication adherence, appointment 
adherence, foot care, and socioeconomic issues. Patient had at 
least 3 visits per year with the community health worker. Nurse 
case managers provided clinical education related to such things 
as medication usage.  Patient received at least 1 visit per year with 
the nurse case manager.   
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(N) Intervention description 
Taviera, 
2011 (6) 
Rate all cause 
hospitalizations 
and ED visits 
Control  
(44) 
Standard care plus - 4 weekly 2-hour diabetes education sessions, 
followed by monthly 2-hour diabetes education sessions.  




Standard care plus - 4 weekly sessions for 2 hours.  Then 5 
monthly education sessions also for 2 hours.  First hour of session 
was spent on education topic led by pharmacist, nutritionist or 
nurse.  In the second hour the clinical pharmacist titrated meds 
based on a home diary 
Borges, 
2011 (12) 
Rate of all 
cause ED visits 
Control (31) Standard Care 
Intervention 
(40) 
Standard care plus - A monthly visit to pharmacist who followed 
clinical and admission data, they provided dietary and 
pharmacological education.  They also provided treatment 





visited the ED 
for all causes 




Standard care plus - A community health worker; a trained 
layperson from the community.  Intervention had a 10 week 1-on-1 
educational component, followed by telephone calls to reinforce 
education and help tackle barriers.  Average of 11 follow-up visits 




Standard care plus - case manager; a registered nurse who 
monitored clinical outcomes as well as educational outcomes, 
helped to incorporate provider treatment plan and refer to 
community resources.  Average of 1 contact per month. 
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Association Measure of ED visits 
(95% Confidence Interval) / 
Association Measure Type 
Wu, 2011 Medium 6 
Control (77) 21 
 
Intervention (81) 14 0.63 (0.35-1.15) / RR 
Aubert, 
1998 Medium 12 
Control (67) 4 
 
Intervention (71) 1 0.24 (0.03-2.06) / RR 
Gary, 
2009 Low 36 
Control (273) 811 
 
Intervention (269) 665 0.84 (0.61-1.15) / IRR 
Taviera, 
2011 Medium 6 
Control (44) 17 
 
Intervention (44) 17 1.00 (0.60-1.68) / RR 
Borges, 







(SD 1.2) 0.70 (0.30-1.64) / EOR 
Babamoto, 
2009 High 6 
Control (108) 15 
 
Community Health 
Worker (104) 7 0.49 (0.21-1.14) / RR 
Case Manager (105) 
12 0.82 (0.40-1.67) / RR 
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Figure 2 – ED Visit Meta-Analysis 
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months) Study Arm (N) 
End of study 
hospitalization 
counts 
Association Measure of 
Hospitalization (95% Confidence 
Interval) / Type of Association 
Measure 
Wu, 2011 Medium 6 
Control (77) 17 
 
Intervention (81) 8 0.45 (0.21-0.98) / RR 
Aubert, 
1998 Medium 12 
Control (67) 4 
 
Intervention (71) 4 1.00 (0.27-3.75) / RR 
Gary, 
2009 Low 36 
Control (273) 317 
 
Intervention (269) 265 0.83 (0.64-1.07) / IRR 
Taviera, 
2011 Medium 6 
Control (44) 7 
 
Intervention (44) 6 0.86 (0.32-2.32) / RR 
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Figure 3 – Hospitalization Meta-analysis 
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Appendix 1 - Search terms 
PubMed 
5/13/14 Diabetes Mellitus, Type 2 AND (Preventive Health Services OR Patient Care 
Management OR Health Education OR Counseling) AND (Emergency Department OR 
Hospitalization OR "Hospitals/utilization"[Mesh]) 
 
CINAHL 




('type 2 diabetes'/exp OR 'type 2 diabetes' OR 'non insulin dependent diabetes 
mellitus'/exp)  AND ('patient care management'/exp OR 'patient care management' OR 'case 
management'/exp OR 'patient education'/exp OR 'patient education' OR 'diabetes 
education'/exp OR 'diabetes education' 'preventative health care' OR 'preventative health 
services') AND ('emergency room'/exp OR 'emergency room' OR 'emergency ward'/exp OR 
'emergency ward' OR 'emergency health service'/exp OR 'hospitalization'/exp OR 
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Appendix 2 – Fulfillment of Disease Management Criteria 
 CM = Case Manager (Registered Nurse or Pharmacist), CHW = Community Health Worker  
Author 
Name, Year Education Coaching Monitoring Care Coordination 
Treatment 
Adjustment Contact frequency 
Method of 
Contact 
Wu, 2011 4 weekly education sessions 
initially 
CM called to 
follow-up 8-16 
weeks later 
   





5 week education program with 
quarterly follow-up 
CM gave guidance 











1 contact per week for 
patients with insulin.  
Contact per 2 weeks 





CM provided clinical education 











CM provided written 




Minimum of 3 
times/year for CHW. 




Taveira, 2011 First hour of session is spent on 
education led by nurse, 












4 weekly 2-hour 
sessions, followed by 5 
monthly 2-hour 
sessions In-person 
Borges, 2011 CM provided dietary and 
pharmacological education. 
 







on algorithm. Monthly In-person 
Babamoto, 
2009 
CHW provided 10 week 1-on-1 
educational sessions, based on 
American Diabetes Association 
standards. 
CHW made follow-




   
Average of 11.3 visits 
over 6 months. 
In-person + 
telephone 
CM provided as-needed 
education based on American 










	   D	  
Appendix 3 –Study Quality Assessment* 
Author/ 
year Study Arm (N) Attrition (%) 
Ascertainment of Utilization 
Outcome Risk of Bias 
Gary, 
2009 
Control (273) 7.3% Chart review and inquiry at local 
hospitals Low Intervention (269) 12.6% 
Wu, 2011 
Control (77) 5.2% 
Self Report Medium	  Intervention (81) 11.0% 
Aubert, 
1998 
Control (67) 28.0% Not clear how 
those lost to follow up 
were distributed in the 




Control (44) 4.5% 
Uncertain Medium Intervention (44) 0.0% 
Borges, 
2011 
Control (31) 0.0% 
Claims Data Medium Intervention (40) 17.5% 
Babamoto, 
2009 
Control (108) 50.0% 
Self Report High 
Community Health 
Worker (104) 28.0% 
Case Manager (105) 43.0% 
*This table is to present common problems that were found during this review, I also compared studies based on the other  
quality metrics described in the methods section (data not published). 
